HB Wealth Management LLC Purchases 791 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

HB Wealth Management LLC raised its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSPFree Report) by 23.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,101 shares of the company’s stock after purchasing an additional 791 shares during the period. HB Wealth Management LLC’s holdings in CRISPR Therapeutics were worth $280,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the company. WealthPlan Investment Management LLC raised its holdings in shares of CRISPR Therapeutics by 3.1% in the fourth quarter. WealthPlan Investment Management LLC now owns 9,663 shares of the company’s stock valued at $605,000 after acquiring an additional 288 shares in the last quarter. Wealthcare Advisory Partners LLC boosted its stake in shares of CRISPR Therapeutics by 7.7% during the first quarter. Wealthcare Advisory Partners LLC now owns 4,200 shares of the company’s stock valued at $286,000 after purchasing an additional 300 shares in the last quarter. E Fund Management Co. Ltd. increased its holdings in CRISPR Therapeutics by 3.3% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,460 shares of the company’s stock valued at $592,000 after buying an additional 303 shares during the period. Westside Investment Management Inc. raised its stake in CRISPR Therapeutics by 4.7% in the first quarter. Westside Investment Management Inc. now owns 7,393 shares of the company’s stock worth $504,000 after buying an additional 332 shares in the last quarter. Finally, Griffin Asset Management Inc. lifted its holdings in CRISPR Therapeutics by 3.5% during the fourth quarter. Griffin Asset Management Inc. now owns 10,453 shares of the company’s stock worth $654,000 after buying an additional 352 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $56.09, for a total value of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares in the company, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 19,582 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $53.10 on Friday. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The stock’s 50-day simple moving average is $56.57 and its 200-day simple moving average is $64.20.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. The company’s revenue was down 99.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.67) earnings per share. As a group, equities analysts predict that CRISPR Therapeutics AG will post -5.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRSP has been the subject of several recent research reports. Wells Fargo & Company reduced their price target on CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating for the company in a research report on Thursday, May 9th. Guggenheim reissued a “neutral” rating on shares of CRISPR Therapeutics in a research report on Friday, June 28th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Barclays decreased their target price on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating for the company in a research report on Thursday, May 9th. Finally, Oppenheimer cut their price target on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $75.71.

Get Our Latest Stock Analysis on CRSP

CRISPR Therapeutics Company Profile

(Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

See Also

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSPFree Report).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.